Clinical trial

Study of Weekly Motexafin Gadolinium (MGd) for Patients With Chronic Lymphocytic…

NCT00290004 · Pharmacyclics LLC., Industry · Completed

Key facts

NCT number NCT00290004
Title Study of Weekly Motexafin Gadolinium (MGd) for Patients With Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma
Official title Phase I/II Trial of Weekly Motexafin Gadolinium (MGd) for Patients With Refractory or Relapsed Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma
Lead sponsor Pharmacyclics LLC., Industry
Status Completed
Phase Phase 1/Phase 2
Study type Interventional
Conditions Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma, Leukemia, Lymphoma
Intervention type Drug
Interventions motexafin gadolinium
Enrollment 35
Start date Nov 1, 2005
Primary completion Feb 1, 2007
Completion Feb 1, 2007
First posted Feb 10, 2006
Last update posted Sep 11, 2008
Countries United States

At a glance

  • 1–9 Study sites
  • No Results posted
  • None Linked FDA submissions

Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.

About ClinicalTrials.gov studies

ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.

Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date:

Browse all ClinicalTrials.gov studies